DENTSPLY SIRONA’s fair value estimate has dropped from $16 to around $13, signaling a significant downward shift in the stock’s outlook. This change comes as analysts raise the discount rate on the company’s future cash flows. The adjustment reflects a higher risk premium in light of evolving operational and market challenges. Stay tuned to find out how to keep track of these developing trends and what they might mean for investors moving forward.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value DENTSPLY SIRONA.

Recent analyst commentary on DENTSPLY SIRONA reveals both optimism and caution regarding the company’s performance and future outlook. Below is a breakdown of the main bullish and bearish takeaways, as seen through the lens of recent research coverage.

???? Bullish Takeaways

UBS maintains a Buy rating and continues to highlight the company’s long-term potential, setting its price target at $23. This suggests confidence in DENTSPLY SIRONA’s recovery and growth prospects despite the recent volatility.

Stifel, while lowering its price target to $13 from $15, pointed to the new CEO’s detailed action plan to return the company to growth. The firm notes that this plan could begin to drive positive change in the second half of 2026. They emphasize potential execution benefits under the current leadership.

???? Bearish Takeaways

JPMorgan reduced its price target from $14 to $12 and keeps a Neutral stance, citing ongoing operational and market challenges.

Piper Sandler cut its price target from $16 to $13, observing that while revenue was slightly ahead of expectations, EBITDA and EPS missed the mark and guidance was lowered across all metrics. The firm notes challenges in the U.S. are larger than anticipated.

William Blair downgraded DENTSPLY SIRONA to Market Perform from Outperform, highlighting that results came in below expectations, guidance was further reduced, and the company is entering another CFO transition. The analyst expresses concern that the turnaround under CEO Dan Scavilla could be more complex and prolonged than previously thought. This may limit potential share upside over the next 12 to 24 months.

Stifel reiterated its Hold rating alongside the price target cut, emphasizing management’s reduction of guidance for 2025 and the immediate impact of another CFO departure.

Taken together, Wall Street analysts are cautious about DENTSPLY SIRONA’s near-term prospects as several firms have lowered their price targets and expressed concern about continued execution and leadership transitions. However, some see potential for growth over the longer term if the new strategies succeed. The consensus leans Neutral at present, with significant emphasis on the need for improved execution and clarity before more optimistic valuation reassessments can occur.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

DENTSPLY SIRONA announced that CFO Matthew E. Garth will leave his position effective November 5, 2025. The company has begun a formal search for his successor.

The company reported $263 million in noncash after-tax impairment charges for the third quarter of 2025. These charges are primarily related to goodwill and intangible assets, attributed to tariffs and lower projected equipment volumes in the U.S.

DENTSPLY SIRONA revised its 2025 earnings guidance. The company now forecasts net sales between $3.6 billion and $3.7 billion and expects constant currency sales to decline 4% to 5% year-over-year.

The Securities and Exchange Commission concluded its investigation into DENTSPLY SIRONA and stated there is no intention to recommend enforcement action following the company's full cooperation.

The Fair Value Estimate has decreased from $16 to approximately $13. This reflects a significant downgrade in the company's perceived intrinsic worth.

The Discount Rate has increased from 9.8% to 10.6%. This indicates that analysts are now assigning a higher risk premium to the company's future cash flows.

The Revenue Growth Forecast remains largely unchanged, with expectations rising very slightly from 2.1% to 2.12% year-over-year.

The Net Profit Margin has dropped from 6.3% to 4.5%, representing a notable decline in expected profitability.

The Future Price-to-Earnings (P/E) Ratio has risen from 17.3x to 20.2x. This signals a higher expected relative valuation despite a reduced earnings outlook.

Narratives are a smarter way to invest because they connect a company’s story to its financial forecasts and fair value. On Simply Wall St, investors share their Narrative, an accessible and dynamic view that explains the “why” behind the numbers. Narratives evolve as news and analysis arrive, helping you quickly see if it is time to buy or sell by comparing Fair Value to the current Price. Dive into the Narrative in the Community, which is home to millions of investors.

Discover the full story shaping DENTSPLY SIRONA’s outlook, and read the original narrative here:

See how management’s new strategies and digital innovation efforts could set up a long-term recovery.

Track developing risks, from cost inflation and U.S. market weakness to ongoing leadership transitions.

Follow dynamic Fair Value estimates and major catalysts so you never miss an update that could impact your decisions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include XRAY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com